Ping An Biomedical Co., Ltd. (PASW) intrinsic value & 10-year financials
Ping An Biomedical Co., Ltd. (PASW) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 3 fiscal years revenue reached to $4.8M, with an average return on invested capital of -27.1%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $4.8M
- ROIC (10-yr avg)
- -27.1%
- Free cash flow (FY2025)
- —
PASW 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $4.8M | -$1.8M | -$0.10 | — | -43.1% | -27.1% |
| FY2024 | — | — | — | — | — | — |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Ping An Biomedical Co., Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Ping An Biomedical Co., Ltd. has historically struggled to out-earn its cost of capital, averaging just -27.1% ROIC.
Ping An Biomedical Co., Ltd. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Ping An Biomedical Co., Ltd. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.